Axatilimab

WITHDRAWN · PHASE2 · Hematopoietic and Lymphatic System Neoplasm

Sponsor declined to fund study due to inability to agree on IP.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.